Insights into pharmacotherapy of malignant glioma in adults

Bibliography

• Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, editors. WHO classification of tumours of the central nervous system. IARC: Lyon, 2007
   Google Scholar
• Walker MD, Green SB, Byar DP, et al. Randomized comparison of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980;303:1323-9
   PubMed Web of Science ®Google Scholar
• Fine HA, Dear KB, Loeffler JS, et al. Meta-analysis of radiation therapy with or without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993;71:2585-97
   PubMed Web of Science ®Google Scholar
• Prados MD, Scott C, Curran WJ Jr, et al. Procarbazine, lomustine and vincristine (PCV) chemotherapy for anaplastic astrocytoma: a retrospective review of Radiation Therapy Oncology Group protocols comparing survival with carmustine or PCV adjuvant chemotherapy. J Clin Oncol 1999;17:3389-95
   PubMed Web of Science ®Google Scholar
• Medical Research Council Brain Tumour Working Party. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high grade astrocytoma: a Medical Research Council Trial. J Clin Oncol 2001;19:509-18
   PubMed Web of Science ®Google Scholar
• Stewart LA. Chemotherapy in adult high grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomized trials. Lancet 2002;359:1011-18
   PubMed Web of Science ®Google Scholar
• Newlands ES, Stevens MF, Wedge SR, et al. Temozolomide. A review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997;23:35-61
   PubMed Web of Science ®Google Scholar
• Brada M, Judson I, Beale P, et al. Phase I dose-excalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer 1999;81:1022-30
   PubMed Web of Science ®Google Scholar
• Ochs K, Kaina B. Apoptosis induced by DNA damage O6-methylguanine is Bcl-2 and caspase-9/3 regulated and Fas/caspase-8 independent. Cancer Res 2000;60:5815-24
   PubMed Web of Science ®Google Scholar
• Brada M, Hoang-Xuan K, Rampling R, et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 2001;12:259-66
   PubMed Web of Science ®Google Scholar
• van den Bent M, Hegi M, Stupp R. Recent developments in the use of chemotherapy in brain tumors. Eur J Cancer 2006;42:582-8
   PubMed Web of Science ®Google Scholar
• Brock CS, Newlands ES, Wedge SR, et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 1998;58:4363-7
   PubMed Web of Science ®Google Scholar
• Wedge SR, Porteous JK, Glaser MG, et al. In vitro evaluation of temozolomide combined with X-irradiation. Anticancer Drugs 1997;8:92-7
   PubMed Web of Science ®Google Scholar
• Van Rijn J, Heimans JJ, Van den Berg J, et al. Survival of human glioma cells treated with various combination of temozolomide and x-rays. Int J Radiat Oncol Biol Phys 2000;47:779-84
   PubMed Web of Science ®Google Scholar
• Stupp R, Dietrich PY, Ostermann Kraljevic S, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002;20:1375-82
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96
   PubMed Web of Science ®Google Scholar
• Taphoorn MJ, Stupp R, Coens C, et al. Health-related quality of life in patients with glioblastoma: a randomized controlled trial. Lancet Oncol 2005;6:937-44
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi M, Mason W, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, van den Bent MJ, et al. Changing paradigms: an update on the multidisciplinary management of malignant glioma. Oncologist 2006;11:165-80
   PubMed Web of Science ®Google Scholar
• Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high grade glioma. Neurology 2007;68:688-90
   PubMedGoogle Scholar
• Yung WKA, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 1999;17:2762-71
   PubMed Web of Science ®Google Scholar
• Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 2006;24:2707-14
   PubMed Web of Science ®Google Scholar
• Van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas: a randomized European Organization for Research and Treatment of Cancer phase III trial. J Clin Oncol 2006;24:2715-22
   PubMed Web of Science ®Google Scholar
• Ochs K, Kaina B. Apoptosis induced by DNA damage O6-methylguanine is Bcl-2 and caspase-9/3 regulated and Fas/caspase-8 independent. Cancer Res 2000;60:5815-24
   PubMed Web of Science ®Google Scholar
• Gerson SL. Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 2002;20:2388-99
   PubMed Web of Science ®Google Scholar
• Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 2004;4:296-307
   PubMed Web of Science ®Google Scholar
• Jagtap P, Szabo C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 2005;4:421-40
   PubMed Web of Science ®Google Scholar
• Grombacher T, Mitra S, Kaina B. Induction of alkyltransferase (MGMT) gene by DNA damaging agents and the glucocorticoid dexamethasone and comparison with the response of base excision repair genes. Carcinogenesis 1996;17:2329-36
   PubMed Web of Science ®Google Scholar
• Esteller M, Hamilton SR, Burger PC, et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999;59:793-7
   PubMed Web of Science ®Google Scholar
• Jaeckle KA, Eyre HJ, Townsend JJ, et al. Correlation of tumor O6 methylguanine DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol 1998;16:3310-15
   PubMed Web of Science ®Google Scholar
• Friedman H, McLendon R, Kerby T, et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to temodal in newly diagnosed malignant glioma. J Clin Oncol 1998;16:3851-7
   PubMed Web of Science ®Google Scholar
• Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350-4
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Godard S, et al. Clinical trial substantiates the predictive value of O6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with with temozolomide. Clin Cancer Res 2004;10:1871-4
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003
   PubMed Web of Science ®Google Scholar
• Eoli M, Menghi F, Bruzzone MG, et al. Methylation of O6-methylguanine DNA methyltransferase and loss of heterozigosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival. Clin Cancer Res 2007;13:2606-13
   PubMed Web of Science ®Google Scholar
• Paz MF, Yaya-Tur R, Rojas-Marcos I, et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 2004;10:4933-8
   PubMed Web of Science ®Google Scholar
• Tolcher AW, Gerson SL, Denis L, et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 2003;88:1004-11
   PubMed Web of Science ®Google Scholar
• Lee SM, Thatcher N, Crowther D, et al. Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. Br J Cancer 1994;69:452-6
   PubMed Web of Science ®Google Scholar
• Payne MJ, Pratap SE, Middleton MR. Temozolomide in the treatment of solid tumours: current results and rationale for dosing/scheduling. Crit Rev Oncol Hematol 2005;53:241-52
   PubMed Web of Science ®Google Scholar
• Hegi ME, Liu L, Herman J, et al. Correlation of O6-Methylguanine Methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 2008;26:4189-99
   PubMed Web of Science ®Google Scholar
• Wick W, Steinbach JP, Kuker WM, et al. One week on/one week off: a novel active regimen for temozolomide for recurrent glioblastoma. Neurology 2004;62:2113-15
   PubMed Web of Science ®Google Scholar
• Brandes AA, Tosoni A, Cavallo G, et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperative di neuro-oncologia (GICNO). Br J Cancer 2006;95:1155-60
   PubMed Web of Science ®Google Scholar
• Perry JR, Mason WP, Belanger K, et al. The temozolomide RESCUE study: a phase II trial of continuous (28/28) dose-intense temozolomide (TMZ) after progression on conventional 5/28 day TMZ in patients with recurrent glioma. J Clin Oncol 2008;26:abstract 2010
   Google Scholar
• Tosoni A, Cavallo G, Ermani M, et al. Is protracted low-dose temozolomide feasible in glioma patients? Neurology 2006;66:427-9
   PubMed Web of Science ®Google Scholar
• Stupp R, Hottinger AF, van den Bent MJ, et al. Frequently asked questions in the medical management of high grade glioma: a short guide with practicalanswers. Ann Oncol 2008;19(Suppl 7):vii209-16
   PubMedGoogle Scholar
• Franceschi E, Omuro AM, Lassman AB, et al. Salvage temozolomide for prior temozolomide responders. Cancer 2005;104:2473-6
   PubMed Web of Science ®Google Scholar
• Wick W, Platten M, Weller M. New (alternative) temozolomide regimens for the treatment of glioma. Neuro-oncol 2009;11:69-79
   PubMedGoogle Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6
   PubMed Web of Science ®Google Scholar
• Dietrich J, Norden A, Wen P. Emerging antiangiogenic treatments for gliomas – efficacy and safety issues. Review. Current Opin Neurol 2008;21:736-44
   PubMed Web of Science ®Google Scholar
• Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature 1992;359:845-8
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76
   PubMed Web of Science ®Google Scholar
• Bao S, Wu Q, Sathornsumetee S, et al. Stem-cell like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006;66:7843-8
   PubMed Web of Science ®Google Scholar
• Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma [abstract]. In: Sixth Meeting of European Association for Neuro-Oncology. Neuro-oncol 2005;7:369
   Web of Science ®Google Scholar
• Pope WB, Lai A, Nghiemphu P, et al. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 2006;66:1258-60
   PubMed Web of Science ®Google Scholar
• Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008;70:779-87
   PubMed Web of Science ®Google Scholar
• Vredenburgh J, Desjardins A, Herndon JE 2nd, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007;13:1253-9
   PubMed Web of Science ®Google Scholar
• Vredenburgh J, Desjardins A, Herndon JE 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25:4722-9
   PubMed Web of Science ®Google Scholar
• Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-80
   PubMed Web of Science ®Google Scholar
• Wagner SA, Desjardins A, Reardon DA, et al. Update on survival from the original phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas [abstract]. J Clin Oncol 2008;26:2021
   Web of Science ®Google Scholar
• Cloughesy TF, Prados MD, Wen PY, et al. Phase II, randomized, noncomparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM) [abstract]. J Clin Oncol 2008;26:2010b
   Web of Science ®Google Scholar
• Kreisl T, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27:740-5
   PubMed Web of Science ®Google Scholar
• Prados MD, Lamborn K, Yung WK, et al. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro-oncol 2006;8:189-93
   PubMed Web of Science ®Google Scholar
• Du R, Lu KV, Petritsch C, et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008;13:206-20
   PubMed Web of Science ®Google Scholar
• Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999;284:1994-8
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Kim J, Ozawa T, et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000;2:306-14
   PubMed Web of Science ®Google Scholar
• Lassman AB, Iwamoto FM, Gutin PH, Abrey LE. Patterns of relapse and prognosis after bevacizumav (BEV) failure in recurrent glioblastoma (GBM) [abstract]. J Clin Oncol 2008;26:2028
   Google Scholar
• Pope WB, Lai A, Nghiemphu P, et al. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 2006;66:1258-60
   PubMed Web of Science ®Google Scholar
• Omuro A, Delattre J-Y. What is the place of bevacizumab and irinotecan in the treatment of glioblastoma and other malignant gliomas? Editorial comment. Curr Opin Neurol 2008;21:717-19
   PubMedGoogle Scholar
• Leon SP, Folkerth RD, Black PM. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 1996;77:362-72
   PubMed Web of Science ®Google Scholar
• Sathornsumetee S, Cao Y, Marcello JE, et al. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 2008;26:271-8
   PubMed Web of Science ®Google Scholar
• Duda DG, Jain RK, Willet CG. Antiangiogenetics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol 2007;25:4033-42
   PubMed Web of Science ®Google Scholar
• Lai A, Filka E, McGibbon B, et al. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys 2008;71:1372-80
   PubMed Web of Science ®Google Scholar
• De Groot JF, Wen PY, Lamborn K, et al. Phase II single arm trial of aflibercept in patients with recurrent temozolomide-resistant glioblastoma: NABTC 0601 [abstract]. J Clin Oncol 2008;26:2020
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11:83-95
   PubMed Web of Science ®Google Scholar
• Di Tommaso E, Frosch MP, Auluck PK, et al. Characterization of blood vessels in brain autopsies of GBM patients who received antiangiogenic treatment [abstract]. J Clin Oncol 2008;26:2009
   Google Scholar
• Jain RK, di Tomaso E, Duda DG, et al. Angiogenesis in brain tumor. Nat Rev Neurosci 2007;8:610-22
   PubMed Web of Science ®Google Scholar
• Zhou Q, Guo P, Gallo JM. Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide. Clin Cancer Res 2008;14:1540-9
   PubMed Web of Science ®Google Scholar
• Carapancea M, Alexandru O, Fetea A, et al. Growth factor receptors signaling in glioblastoma cells: therapeutic implications. J Neurooncol 2009;92:137-47
   PubMed Web of Science ®Google Scholar
• Idbah A, Ducrey F, Sierra Del Rio M, et al. Therapeutic application of noncytotxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors. Oncologist 2008;13:978-92
   PubMedGoogle Scholar
• Nicholas MK, Lukas RV, Jafri NF, et al. Epidermal growth factor receptor-mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res 2006;12:7261-70
   PubMed Web of Science ®Google Scholar
• Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004;64:6892-9
   PubMed Web of Science ®Google Scholar
• Pelloski C, Ballman K, Furth A, et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol 2007;25:2288-94
   PubMed Web of Science ®Google Scholar
• Peereboom DM, Brewer C, Stevens GHJ, et al. Phase II trial of erlotinib with temozolomide and concurrent radiation therapy post-operatively in patients with newly diagnosed glioblastoma multiforme. Neuro-oncol 2005;6:379 TA-41 (abstr.)
   Google Scholar
• Prados MD, Lamborn KR, Chang S, et al. Phase I study of erlotinib HCI alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro-oncol 2006;8:67-78
   PubMed Web of Science ®Google Scholar
• Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005;353:2012-24
   PubMed Web of Science ®Google Scholar
• Haas-Kogan DA, Prados MD, Tihan T, et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 2005;97:880-7
   PubMed Web of Science ®Google Scholar
• Rich JN, Reardon DA, Peery T, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004;22:133-42
   PubMed Web of Science ®Google Scholar
• Brown PD, Krishnan S, Sarkaria JN, et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblaastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol 2008;26:5603-9
   PubMed Web of Science ®Google Scholar
• Franceschini E, Cavallo G, Lonardi S, et al. Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer 2007;96:1047-51
   PubMedGoogle Scholar
• Doherty L, Gigas DC, Cesari S, et al. Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology 2006;67:156-8
   PubMed Web of Science ®Google Scholar
• Reardon DA, Quinn JA, Vredenburgh JJ, et al. Phase I trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res 2006;12:860-8
   PubMed Web of Science ®Google Scholar
• Prados M, Chang S, Butowski C, et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol 2009;27:579-84
   PubMed Web of Science ®Google Scholar
• Westphal M, Hilt DC, Bortey E, et al. A phase III trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncol 2003;5:79-88
   PubMed Web of Science ®Google Scholar
• Westphal M, Ram Z, Riddle V, et al. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien) 2006;148:269-75
   PubMed Web of Science ®Google Scholar
• Limentani SA, Asher A, Heafner M, et al. A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme. J Neurooncol 2005;72:241-4
   PubMed Web of Science ®Google Scholar
• Brandes AA, Ermani M, Turazzi S, et al. Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase ii study. J Clin Oncol 1999;17:645-50
   PubMed Web of Science ®Google Scholar
• Couldwell WT, Hinton DR, Surnock AA, et al. Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clin Cancer Res 1996;2:619-22
   PubMed Web of Science ®Google Scholar
• Chen TC, Su S, Fry D, Liebes L. Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma. Cancer 2003;97(9 Suppl):2363-73
   PubMed Web of Science ®Google Scholar
• Spence AM, Peterson RA, Scharnhorst JD, et al. Phase II study of concurrent continous temozolomide (TMZ) and tamoxifen (TMX) for recurrent malignant astrocytic gliomas. J Neurooncol 2004;70:91-5
   PubMed Web of Science ®Google Scholar
• Gupta V, Su YS, Wang W, et al. Enhancement of glioblastoma cell killing by combination treatment with temozolomide and tamoxifen or hypericin. Neurosurg Focus 2006;20(4):E20
   PubMedGoogle Scholar
• Muanza T, Shenouda G, Souhami L, et al. High dose tamoxifen and radiotherapy in patients with glioblastoma multiforme: a phase IB study. Can J Neurol Sci 2000;27:302-6
   PubMedGoogle Scholar
• Robins HI, Won M, Seiferheld WF, et al. Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-0021. Neuro-oncol 2006;8:47-52
   PubMed Web of Science ®Google Scholar
• Wick W, Wick A, Schulz JB, et al. Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase. Cancer Res 2002;62:1915-19
   PubMed Web of Science ®Google Scholar
• Stupp R, Goldbrunner R, Neyns B, et al. Phase I/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients with newly diagnosed glioblastoma. ASCO Annual Meeting Proceedings Part I 2007 [abstract 2000]. J Clin Oncol 2007;25(Suppl):75s
   Google Scholar
• Tuettenberg J, Grobholz R, Korn T, et al. Continous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme. J Cancer Res Clin Oncol 2005;131:31-40
   PubMed Web of Science ®Google Scholar
• Reardon DA, Quinn JA, Vredenburgh JA, et al. Phase II Trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer 2005;103:329-38
   PubMed Web of Science ®Google Scholar
• Soffietti R, Leoncini B, Rudà R. New developments in the treatment of malignant gliomas. Expert Rev Neurother 2007;7:1313-25
   PubMedGoogle Scholar
• Yung WKA, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodar Brain Tumor Group. J Clin Oncol 1999;17:2762-71
   PubMed Web of Science ®Google Scholar
• Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473-9
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 2003;21:2525-8
   PubMed Web of Science ®Google Scholar
• Soffietti R. Chemotherapy of anaplastic oligodendroglial tumours. Expert Opin Pharmacother 2004;5:295-306
   PubMed Web of Science ®Google Scholar
• Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas. Neurology 2004;63:904-6
   PubMed Web of Science ®Google Scholar
• Cairncross G, Seiferheld W, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 2006;24:2707-14
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas: a randomized European Organization for Research and Treatment of Cancer Phase III trial. J Clin Oncol 2006;24:2715-22
   PubMed Web of Science ®Google Scholar
• Abrey LE, Louis DN, Paleologos N, et al. Survey of treatment recommendations for anaplastic oligodendroglioma. Neuro-oncol 2007;9:314-18
   PubMed Web of Science ®Google Scholar